HOME >> BIOLOGY >> NEWS
Breakthrough technology from Pall increases platelet availability and safety

East Hills, NY (October 5, 2005) -- Pall Corporation (NYSE: PLL) announced today FDA clearance to market the new Pall AcrodoseTM PL System. This is the first whole blood derived platelet system for pre-storage pooling and testing of leukoreduced whole blood derived platelets resulting in a transfusion-ready product for the hospital. This unique product increases the availability of lifesaving platelets, enhances patient safety and is more cost-effective for the hospital.

"Adequate platelet availability in some communities can sometimes be a challenge," says Allan Ross, President of Pall Medical. "The Acrodose PL System provides an opportunity for blood centers and hospitals to increase the availability of bacterially tested, leukoreduced, and pooled whole blood derived platelets in a cost-effective manner."

Platelets are derived from donors in either a one-to-two hour procedure called apheresis or from standard whole blood collections. Apheresed platelets are limited by donor availability. They are also time consuming and capital intensive to obtain. Regardless of which collection process is used, bacterial contamination of platelets is the leading infectious cause of illness and death from a blood transfusion. Single donor platelets are tested for bacterial contamination using a sensitive culture detection method such as Pall's eBDS, enhanced bacterial system. Whole blood derived platelet units on the other hand are tested using less sensitive methods due to cost, product loss, and logistical constraints of testing several individual units to obtain a standard therapeutic dose. This has resulted in a disparity of test sensitivities as well as underutilization of a valuable blood resource.

The new Acrodose PL System enables blood centers to pool individual whole blood derived platelets prior to storage and conduct a single bacterial contamination test with its integrated Pall eBDS technology. Studies using the Pall eBDS System with pooled p
'"/>

Contact: Marcia Katz
marcia_katz@pall.com
516-801-9128
Pall Corporation
6-Oct-2005


Page: 1 2

Related biology news :

1. Breakthrough developments in rheumatoid arthritis reported
2. Breakthrough for treatment of fatal heart condition
3. Breakthrough vaccine to treat chemo-resistant ovarian cancer
4. Breakthrough in understanding type 2 diabetes as key genes identified
5. Breakthrough in nanodevice synthesis revolutionizes biological sensors
6. Breakthrough for future exploration unrecoverable gas reserves
7. Breakthrough by MUHC researcher has major implications
8. Breakthrough offers new tool for studying degenerative disease
9. Breakthrough in brain injury study at University of Leicester
10. Breakthrough for stem cell research
11. Sciences Breakthrough of the Year: Watching evolution in action

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/18/2020)... ... July 16, 2020 , ... A study has been published ... Neoasis™ active noise control device to attenuate typical noises in a simulated neonatal ... the alarm sounds from patient monitors, ventilators and other bedside devices that would ...
(Date:7/2/2020)... Calif. (PRWEB) , ... July 01, 2020 , ... ... company, presented its phase 1a findings of Neihulizumab, a biologic for the treatment ... in June 2020. Led by hemato-oncologist Dr. Paul J Martin of the Fred ...
(Date:6/28/2020)... ... 25, 2020 , ... In an upcoming episode scheduled for the fall of ... Testing solutions (POCT). Check local listings for more info. , Today, the majority of ... shipped to labs throughout the country. Results are then available several days later. Now, ...
Breaking Biology News(10 mins):
(Date:9/1/2020)... SOUTH RIDING, Va. (PRWEB) , ... September 01, ... ... search firm for life sciences, biotechnology, and diagnostics companies, has announced the placement ... Technologies . Averill will be responsible for leading all financial operations and implementing ...
(Date:8/12/2020)... ... August 11, 2020 , ... ... validation engineering firm, is making available for free its new white paper ... concurrent transport simulation testing into today’s biologics licensing application (BLA). In response, ...
(Date:7/31/2020)... , ... July 29, 2020 , ... R3 Stem Cell ... for only $3950. With 50 million stem cells total, patients may choose which extremities ... therapy works for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord ...
(Date:7/31/2020)... ... ... eSource has long been touted as the solution to high data management ... reasons it did not take off as quickly as people initially expected, and where ... towards capturing data electronically for clinical trials and then repurposing it for downstream analysis, ...
Breaking Biology Technology:
Cached News: